evacetrapib
Jump to navigation
Jump to search
Introduction
Investigational drug.
Indications
Dosage
Mechanism of action
- CETP inhibitor
- increases HDL cholesterol, lowers LDL cholesterol
- no reduction in cardiovascular events or mortality in high-risk patients[2]
More general terms
References
- ↑ Nicholls SJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011 Nov 16; 306:2099. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22089718 <Internet> http://jama.ama-assn.org/content/306/19/2099.full
Cannon CP. High-density lipoprotein cholesterol as the holy grail. JAMA 2011 Nov 16; 306:2153. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22089726 - ↑ 2.0 2.1 Lincoff AM, Nicholls SJ, Riesmeyer JS et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017 May 18; 376:1933. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28514624 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1609581